• SNG001, an experimental inhaled nebulised interferon beta-1a, reduced the odds of developing severe COVID-19 disease or dying by 79%, finds new randomised, double-blind, placebo-controlled, phase 2 trial. https://www.thelancet.com/journals/lanres/article/piis2213-2600(20)30511-7/fulltext 5 comments 13/11/2020 science

Linking pages

Related searches:

Search whole site: site:www.thelancet.com

Search title: SNG001, an experimental inhaled nebulised interferon beta-1a, reduced the odds of developing severe COVID-19 disease or dying by 79%, finds new randomised, double-blind, placebo-controlled, phase 2 trial.

See how to search.